A Multicenter, One Group, Open-label Study to Evaluate the Safety and Efficacy of Pletaal(Cilostazol) as BID for up to 24 Weeks Exposure in Subjects With Vasospastic Angina (STELLA Extension)
Phase of Trial: Phase III
Latest Information Update: 16 Sep 2016
At a glance
- Drugs Cilostazol (Primary)
- Indications Angina pectoris
- Focus Registrational; Therapeutic Use
- Acronyms STELLA_Ext
- Sponsors Korea Otsuka Pharmaceutical
- 28 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 04 Sep 2014 Modified inclusion and exclusion criteria as reported in ClinicalTrials.gov record.
- 25 Mar 2014 New trial record